A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC
概览
- 阶段
- 1 期
- 干预措施
- EGF816
- 疾病 / 适应症
- EGFR-mutant Non-small Cell Lung Cancer
- 发起方
- Novartis Pharmaceuticals
- 入组人数
- 105
- 试验地点
- 12
- 主要终点
- Number of patients with adverse events and serious adverse events
- 状态
- 进行中（未招募）
- 最后更新
- 3个月前
概览
简要总结
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).
详细描述
This is a Phase Ib, open label, non-randomized dose escalation study of EGF816 in combination with ribociclib, trametinib, or LXH254, followed by dose expansion of EGF816 in combination with ribociclib, trametinib, LXH254, INC280, or gefitinib in adult patients with advanced EGFR-mutant NSCLC. During the dose escalation part, patients were assigned to the addition of trametinib, ribociclib, or LXH254 to EGF816. Following determination of the recommended dose for the combination of EGF816 + trametinib, EGF816 + ribociclib, and EGF816 + LXH254, patients could be enrolled to the dose expansion arms of each of these combinations. Patients could also be assigned to EGF816 + INC280. The planned arm EGF816 + gefitinib in dose expansion was not opened for enrollment.
研究者
入排标准
入选标准
- •Patients must have histologically or cytologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.
- •Requirements of EGFR mutation status and prior lines of treatment:
- •Treatment naive patients, who have locally advanced or metastatic NSCLC with EGFR sensitizing mutation (e.g., L858R and/or ex19del), have not received any systemic antineoplastic therapy for advanced NSCLC and are eligible to receive EGFR TKI treatment. Patients with EGFR exon 20 insertion/duplication are not eligible. Note: patients who have received only one cycle of chemotherapy in the advanced setting are allowed.
- •Patients who have locally advanced or metastatic NSCLC with EGFR sensitizing mutation AND an acquired T790M mutation (e.g., L858R and/or ex19del, T790M+) following progression on prior treatment with a 1st-generation EGFR TKI or 2nd-generation EGFR TKI. These patients may not have received more than 4 prior lines of antineoplastic therapy in the advanced setting, including EGFR TKI, and may not have received any agent targeting EGFR T790M mutation (i.e., 3rd-generation EGFR TKI).
- •Patients who have locally advanced or metastatic NSCLC with EGFR sensitizing mutation and a "de novo" T790M mutation (i.e., no prior treatment with any agent known to inhibit EGFR including EGFR TKI). These patients may not have received more than 3 prior lines of antineoplastic therapy in the advanced setting, and may not have received any prior 3rd generation EGFR TKI.
- •Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy during therapy on this study, and at screening if an archival tumor sample obtained since the diagnosis of advanced disease (1L patients) or since last treatment failure (2L+ patients) is not available.
排除标准
- •Patients with a history or presence of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis.
- •Patients with unstable brain metastases.
- •Patients with a history of another malignancy.
- •Patients with a known history of human immunodeficiency virus (HIV) seropositivity.
- •Patients with clinically significant, uncontrolled heart disease.
- •Patients participating in additional parallel investigational drug or medical device studies.
- •Prior therapies:
- •Patients who have been treated with EGFR TKI in the adjuvant setting within 6 months, unless acquired EGFR T790M is present in a tumor or blood sample obtained since the discontinuation of the EGFR TKI.
- •Patients who have been treated with prior EGFR TKI targeting T790M (3rd generation).
- •Patients who have been treated with systemic anti-neoplastic therapy within:
研究组 & 干预措施
Arm 3
EGF816 + LXH254 in escalation phase
干预措施: EGF816
Arm 3
EGF816 + LXH254 in escalation phase
干预措施: LXH254
Arm 2
EGF816 + ribociclib in escalation phase
干预措施: EGF816
Arm 2
EGF816 + ribociclib in escalation phase
干预措施: ribociclib
Arm 1
EGF816+ trametinib in escalation phase
干预措施: EGF816
Arm 1
EGF816+ trametinib in escalation phase
干预措施: trametinib
Arm A
EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
干预措施: EGF816
Arm A
EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
干预措施: INC280
Arm B
EGF816 + trametinib in expansion phase
干预措施: EGF816
Arm B
EGF816 + trametinib in expansion phase
干预措施: trametinib
Arm C
EGF816 + ribociclib in expansion phase
干预措施: EGF816
Arm C
EGF816 + ribociclib in expansion phase
干预措施: ribociclib
Arm D
EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
干预措施: EGF816
Arm D
EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
干预措施: LXH254
Arm E
EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
干预措施: EGF816
Arm E
EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
干预措施: LXH254
Arm F
EGF816 + gefitinib in expansion phase
干预措施: EGF816
Arm F
EGF816 + gefitinib in expansion phase
干预措施: gefitinib
Arm G
EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
干预措施: EGF816
Arm G
EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
干预措施: INC280
结局指标
主要结局
Number of patients with adverse events and serious adverse events
时间窗: Every day until study end, approximately 4 years
Assess safety and tolerability including incidence of dose limiting toxicities, adverse events, and serious adverse events.
Number of participants with DLTs in the first cycle of combination (Dose escalation only)
时间窗: 28 days
A Dose-Limiting Toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of combination treatment during the dose escalation part of the study. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
Number of participants with dose interruptions and reductions
时间窗: From first dose until study ends, approximately 4 years
Assessment of tolerability. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments may be permitted in order to allow patients to continue the study treatment.
Dose intensity of study drugs
时间窗: From first dose until study ends, approximately 4 years
Dose intensity is computed as the ratio of actual cumulative dose received to actual duration of exposure.
ORR2
时间窗: Every 8-12 weeks until study ends, approximately 4 years
Modified objective response rate (ORR2) per RECIST v1.1 (taking as baseline the most recent assessment prior to initiating combination)
次要结局
- ORR(Every 8-12 weeks until study ends, approximately 4 years)
- PFS(Every 8-12 weeks until study ends, approximately 4 years)
- DCR(Every 8-12 weeks until study ends, approximately 4 years)
- DOR(Every 8-12 weeks until study ends, approximately 4 years)
- Time to response(Every 8-12 weeks until study ends, approximately 4 years)
- Area under the plasma concentration-time curve (AUC) of study drugs(From pre-dose up to 8 hours post-dose on Day 15 of Cycle 1. One cycle=28 days.)
- Maximum observed plasma concentration (Cmax) of study drugs(From pre-dose up to 8 hours post-dose on Day 15 of Cycle 1. One cycle=28 days.)